Neurosyphilis
Neurosyphilis — infection of the central nervous system by Treponema pallidum — has re-emerged as a clinically significant entity, driven by rising syphilis rates globally, particularly among men who have sex with men (MSM) and individuals with HIV co-infection. A critical concept is that neuroinvasion occurs early in the course of syphilis, and neurosyphilis can manifest at any stage of the disease. The clinical spectrum ranges from asymptomatic CSF abnormalities to devastating late manifestations such as general paresis and tabes dorsalis. Neurologists must maintain a high index of suspicion, as neurosyphilis is eminently treatable with IV penicillin, and delayed diagnosis leads to irreversible neurologic damage.
Bottom Line
- Can occur at ANY stage: Neurosyphilis is not just a late complication — CSF invasion occurs within hours to days of primary infection; clinical manifestations span early (meningitis, meningovascular) and late (general paresis, tabes dorsalis) forms
- Argyll Robertson pupils are pathognomonic: Small, irregular pupils that accommodate but do not react to light (light-near dissociation) — the classic finding of neurosyphilis
- Diagnosis requires serum + CSF: Serum RPR/VDRL for screening, FTA-ABS/TP-PA for confirmation; CSF VDRL is specific (~100%) but insensitive (50–70%); CSF FTA-ABS is sensitive but less specific
- LP indications: Any neurologic, ophthalmologic, or otologic symptoms; HIV+ with RPR ≥1:32 or CD4 <350; treatment failure
- IV penicillin G is the treatment: 18–24 million units/day for 10–14 days; no proven alternative with equivalent efficacy
- HIV co-infection increases risk: Higher rates of neurosyphilis, potentially atypical presentations, and same treatment with closer follow-up
Epidemiology and Resurgence
After decades of declining incidence following the introduction of penicillin, syphilis rates have risen sharply since the early 2000s. The CDC reported over 207,000 total syphilis cases in the United States in 2023, the highest number in decades.
- Rising rates: Primary and secondary syphilis rates have increased >70% in the past decade in the US; similar trends observed in Europe, Australia, and Asia
- Demographics: Initially concentrated among MSM; now increasing among heterosexual populations and women (with concomitant rise in congenital syphilis)
- HIV co-infection: Syphilis and HIV are frequently co-morbid; HIV-positive individuals have a higher risk of developing neurosyphilis and may do so earlier in the disease course
- Neurosyphilis incidence: Estimated at 0.5–1.0 per 100,000 in the general population; higher among HIV-positive individuals with syphilis (up to 15–25% may have CSF abnormalities)
- Challenge: Many clinicians have limited experience with neurosyphilis due to its historical rarity — delayed diagnosis is common
Pathophysiology
T. pallidum invades the CNS early in the course of infection. Studies have demonstrated CSF abnormalities in up to 25–40% of patients with early syphilis, indicating that neuroinvasion is the rule rather than the exception. However, most patients clear the organism spontaneously without developing clinical neurosyphilis. The factors that determine progression from asymptomatic neuroinvasion to clinical disease are incompletely understood but include host immune status (especially CD4 count in HIV co-infection), spirochetal burden, and possibly strain virulence.
Natural History of Syphilis — Neurologic Relevance
- Primary syphilis: Chancre at inoculation site; CNS invasion already occurring
- Secondary syphilis: Disseminated infection (rash, mucous patches, condylomata lata); headache and meningismus may indicate early neurosyphilis
- Latent syphilis: No clinical manifestations; early latent (<1 year) vs. late latent (>1 year or unknown duration)
- Tertiary syphilis: Cardiovascular syphilis (aortitis), gummatous syphilis, late neurosyphilis (general paresis, tabes dorsalis) — develops in 15–40% of untreated patients years to decades after initial infection
- Key point: The traditional classification of neurosyphilis as "early" vs. "late" is clinically useful but artificial — overlap is common, and any form can occur at any time
Clinical Manifestations
Early Neurosyphilis
Asymptomatic Neurosyphilis
- Definition: CSF abnormalities (pleocytosis, elevated protein, reactive CSF VDRL) without neurologic symptoms
- Significance: Indicates active CNS infection that may progress to symptomatic forms if untreated
- Detection: Found incidentally when LP is performed for other indications in a syphilis-positive patient
- Treatment: Same as symptomatic neurosyphilis — IV penicillin G
Syphilitic Meningitis
- Timing: Typically within the first 1–2 years of infection (can occur during secondary syphilis)
- Presentation: Headache, meningismus, nausea/vomiting; cranial neuropathies are common
- Cranial nerve involvement: CN VII (facial palsy) and CN VIII (sensorineural hearing loss, vestibular dysfunction) are most frequently affected; any cranial nerve can be involved
- Ocular syphilis: Uveitis, optic neuritis, papillitis, retinitis — may be the presenting or sole manifestation; any patient with unexplained uveitis should be tested for syphilis
- Otosyphilis: Sensorineural hearing loss, tinnitus, vertigo — may mimic Meniere disease; may occur at any stage
- CSF: Lymphocytic pleocytosis (50–500 cells/μL), elevated protein, normal or low glucose
Meningovascular Syphilis
- Timing: Typically 5–12 years after primary infection (range: months to years)
- Pathology: Heubner arteritis (proliferative endarteritis of medium-large arteries) and Nissl-Alzheimer arteritis (small vessel involvement)
- Presentation: Stroke in a young patient — especially in the MCA territory; may be preceded by weeks of headache, personality change, or malaise (prodromal meningitis)
- Key differential: Must be considered in any young patient with stroke, particularly if there are risk factors for syphilis; standard stroke workup may show large-vessel irregularity on angiography mimicking vasculitis
- Spinal cord involvement: Meningovascular syphilis can cause spinal cord infarction or syphilitic myelitis
When to Suspect Early Neurosyphilis
- Unexplained cranial neuropathy, especially CN VII or CN VIII
- Acute or subacute uveitis, optic neuritis, or retinitis of unclear etiology
- Stroke in a young patient without conventional vascular risk factors
- Aseptic meningitis with lymphocytic pleocytosis and negative viral workup
- Unexplained sensorineural hearing loss or vertigo, especially in at-risk populations
- Any of the above in a patient with HIV or known syphilis history demands immediate syphilis testing
Late Neurosyphilis
General Paresis (Dementia Paralytica)
- Timing: 10–25 years after primary infection
- Pathology: Chronic meningoencephalitis with direct parenchymal invasion by T. pallidum; cortical atrophy, especially frontal and temporal lobes
- Presentation: Progressive dementia with prominent psychiatric and behavioral features
- Mnemonic — PARESIS:
- Personality changes (irritability, apathy, grandiosity)
- Affect abnormalities (depression, mania, psychosis)
- Reflexes hyperactive
- Eye (Argyll Robertson pupils)
- Sensory deficits (decreased proprioception, vibration)
- Intellect declining (progressive dementia)
- Speech abnormalities (dysarthria, tremulous speech)
- Imaging: Cortical atrophy, particularly frontal and temporal; may mimic Alzheimer disease or frontotemporal dementia on neuroimaging
- Prognosis: Partially reversible with treatment if diagnosed early; irreversible damage occurs with advanced disease
Tabes Dorsalis
- Timing: 15–25 years after primary infection
- Pathology: Degeneration of the posterior columns and dorsal root ganglia
- Presentation:
- Lightning pains: Sudden, severe, lancinating pains in the legs (or abdomen — "tabetic crises") lasting seconds to minutes
- Sensory ataxia: Progressive gait unsteadiness worse in darkness; positive Romberg sign; wide-based stamping gait
- Loss of proprioception and vibration sense: Posterior column dysfunction
- Argyll Robertson pupils: Bilateral small, irregular pupils that accommodate but do not react to light
- Areflexia: Loss of deep tendon reflexes, especially at the knees and ankles
- Charcot joints (neuropathic arthropathy): Painless joint destruction, most commonly affecting the knees; due to loss of proprioceptive feedback
- Bladder dysfunction: Overflow incontinence from loss of afferent signaling
- Treatment response: Lightning pains and ataxia may improve somewhat with treatment, but posterior column damage is often irreversible
Argyll Robertson Pupils
- Description: Bilateral small (<3 mm), irregular pupils with light-near dissociation — pupils constrict with accommodation (near response) but do not react to light
- Mechanism: Thought to involve damage to the pretectal neurons in the dorsal midbrain that mediate the pupillary light reflex, while sparing the more ventral accommodation pathway
- Mnemonic: "Accommodates but does not react" — or "Prostitute's pupil" (accommodates but doesn't react — a historical, now considered outdated and inappropriate, but widely known mnemonic)
- Differential of light-near dissociation: Neurosyphilis (classic), dorsal midbrain syndrome (Parinaud), diabetes mellitus (Adie-like pupils), aberrant regeneration of CN III, bilateral optic neuropathy (afferent defect)
- Key distinction from Adie tonic pupil: Argyll Robertson pupils are bilateral and small; Adie pupil is typically unilateral and large (dilated)
| Form of Neurosyphilis | Timing Post-Infection | Key Features | CSF Findings |
|---|---|---|---|
| Asymptomatic | Any stage | No neurologic symptoms; abnormal CSF | Pleocytosis, elevated protein, reactive VDRL |
| Syphilitic meningitis | Months–2 years | Headache, cranial neuropathies (CN VII, VIII), uveitis | Lymphocytic pleocytosis, elevated protein |
| Meningovascular | 5–12 years | Stroke (young patient, MCA territory), prodromal headache | Lymphocytic pleocytosis, elevated protein; angiography shows arteritis |
| General paresis | 10–25 years | Progressive dementia, psychiatric symptoms, Argyll Robertson pupils | Elevated protein, lymphocytic pleocytosis, reactive VDRL |
| Tabes dorsalis | 15–25 years | Lightning pains, sensory ataxia, Argyll Robertson pupils, areflexia, Charcot joints | May have mild pleocytosis or normal CSF in late disease |
Diagnosis
Serologic Testing
The diagnosis of neurosyphilis requires a combination of serologic screening, confirmatory testing, and CSF analysis. No single test is perfectly sensitive and specific.
| Test | Type | Sensitivity | Specificity | Clinical Use |
|---|---|---|---|---|
| RPR / VDRL (serum) | Non-treponemal (screening) | 78–86% (primary), 100% (secondary) | 85–99% | Screening and monitoring treatment response; titers decline with treatment |
| FTA-ABS (serum) | Treponemal (confirmatory) | 84% (primary), ~100% (secondary and late) | ~96% | Confirmatory; remains positive for life |
| TP-PA (serum) | Treponemal (confirmatory) | ~85–100% | ~96–99% | Alternative confirmatory test; remains positive for life |
| CSF VDRL | Non-treponemal (CSF) | 50–70% | ~99–100% | Most specific CSF test — a reactive result is diagnostic; but insensitive — negative does not exclude neurosyphilis |
| CSF FTA-ABS | Treponemal (CSF) | ~95–100% | ~70–85% | Sensitive but less specific — a negative result makes neurosyphilis very unlikely; a positive result must be interpreted with caution (false positives from blood contamination) |
Diagnostic Algorithm for Neurosyphilis
- Step 1: Serum non-treponemal test (RPR or VDRL) — if reactive, proceed to confirmatory treponemal test
- Step 2: Serum treponemal test (FTA-ABS or TP-PA) — if both reactive, syphilis confirmed
- Step 3: If neurologic, ophthalmologic, or otologic symptoms → perform LP
- CSF interpretation: Reactive CSF VDRL is diagnostic; if CSF VDRL is non-reactive but clinical suspicion is high, consider CSF FTA-ABS and overall CSF profile (pleocytosis ≥5 WBC/μL, elevated protein >45 mg/dL)
- Prozone phenomenon: False-negative non-treponemal tests in secondary syphilis due to very high antibody titers — request diluted sample if clinical suspicion is high
- Reverse algorithm: Some labs now screen with a treponemal test first (EIA/CIA) — if reactive, reflexed to RPR/VDRL; be aware of discordant results (positive treponemal, negative non-treponemal in early primary or late latent syphilis)
Indications for Lumbar Puncture
| Indication | Rationale |
|---|---|
| Any neurologic symptoms (headache, vision changes, hearing loss, cognitive decline, focal deficits, gait abnormality) | Direct evaluation for CNS infection |
| Ophthalmologic symptoms (uveitis, optic neuritis, visual loss) | Ocular syphilis frequently co-occurs with neurosyphilis |
| Otologic symptoms (hearing loss, tinnitus, vertigo) | Otosyphilis may indicate CNS involvement |
| HIV-positive with serum RPR ≥1:32 | High titer correlates with increased risk of neurosyphilis in HIV |
| HIV-positive with CD4 <350 cells/μL | Impaired immune control of T. pallidum in the CNS |
| Treatment failure (fourfold rise or failure of fourfold decline in serum RPR) | Persistent or re-emerging infection may indicate occult CNS disease |
| Late latent syphilis or syphilis of unknown duration | Some guidelines recommend LP; others suggest it only with neurologic symptoms |
Treatment
First-Line Therapy
Intravenous penicillin G remains the gold standard for neurosyphilis. The goal is to achieve treponemicidal levels in the CSF, which requires sustained high-dose parenteral administration.
| Regimen | Dosing | Duration | Notes |
|---|---|---|---|
| IV aqueous penicillin G (preferred) | 18–24 million units/day (3–4 million units IV every 4 hours) | 10–14 days | Gold standard; achieves reliable treponemicidal CSF levels |
| IM procaine penicillin + probenecid (alternative) | Procaine penicillin 2.4 million units IM daily + probenecid 500 mg PO four times daily | 10–14 days | Acceptable alternative if IV access is not feasible; probenecid blocks renal excretion to maintain CSF levels |
| Penicillin allergy | Penicillin desensitization is recommended | — | No alternative has been proven equivalent; ceftriaxone (2 g IV daily × 10–14 days) is sometimes used but data are limited |
Jarisch-Herxheimer Reaction
- Definition: Acute febrile reaction occurring within 2–24 hours of initiating treatment for syphilis
- Symptoms: Fever, rigors, headache, myalgia, hypotension; may transiently worsen existing neurologic symptoms
- Mechanism: Release of cytokines in response to lysis of spirochetes
- Frequency: Common in early syphilis (50–75%); less frequent in late syphilis (~15–25%)
- Management: Supportive care (antipyretics, IV fluids); self-limited (resolves within 12–24 hours); do not discontinue antibiotics
- Caution: In meningovascular syphilis, there is a theoretical risk that the Herxheimer reaction could worsen cerebral inflammation — close monitoring recommended
Treatment of Ocular and Otosyphilis
- Ocular syphilis: Treated with the same regimen as neurosyphilis (IV penicillin G 18–24 MU/day for 10–14 days) regardless of whether CSF is abnormal
- Otosyphilis: Same treatment as neurosyphilis; hearing loss may be partially or fully reversible with early treatment
- Rationale: The eye and inner ear are extensions of the CNS; even with normal CSF, treat as neurosyphilis to ensure adequate treatment of these compartments
Follow-Up and Treatment Monitoring
CSF Follow-Up
- Repeat LP: Recommended at 6 months after treatment; if CSF still abnormal, repeat every 6 months until normalization
- Expected course: CSF WBC should decline by 6 months and normalize by 2 years; CSF protein normalizes more slowly; CSF VDRL should become non-reactive
- Re-treatment criteria: CSF cell count has not decreased at 6 months, or CSF has not fully normalized by 2 years — re-treat with IV penicillin G
- Serum RPR: Should demonstrate a fourfold decline within 6–12 months; may not fully serorevert in late syphilis
Prognosis by Form
| Form | Response to Treatment | Key Prognostic Factors |
|---|---|---|
| Asymptomatic | Excellent; prevents progression to symptomatic forms | Early detection and treatment |
| Syphilitic meningitis | Good; cranial neuropathies often improve or resolve | CN VIII involvement may cause permanent hearing loss |
| Meningovascular | Variable; prevents further strokes but established infarcts are irreversible | Extent of infarction at diagnosis |
| General paresis | May stabilize or partially improve if treated early; advanced disease often irreversible | Severity of cognitive impairment at diagnosis |
| Tabes dorsalis | Lightning pains may improve; ataxia and posterior column dysfunction often persistent | Degree of posterior column degeneration (structural damage is irreversible) |
HIV Co-Infection and Neurosyphilis
The intersection of HIV and syphilis creates unique diagnostic and management challenges. HIV-positive individuals are at significantly higher risk for developing neurosyphilis and may have atypical or accelerated presentations.
| Consideration | HIV-Positive Patients | HIV-Negative Patients |
|---|---|---|
| Risk of neurosyphilis | Increased; especially if CD4 <350 or RPR ≥1:32 | Standard risk based on stage and duration |
| Presentation | May have atypical or overlapping presentations; uveitis and CN8 involvement more common | More classic presentations |
| Serology | May have unusual serologic patterns (false-negative RPR, persistently high titers post-treatment) | Standard interpretation |
| CSF interpretation | HIV itself causes CSF pleocytosis and elevated protein — interpretation is challenging; VDRL remains specific | Standard CSF interpretation |
| Treatment | Same regimen (IV penicillin G); ART initiation/optimization also important | Same regimen |
| Follow-up | Closer monitoring recommended (CSF at 3–6 months); higher rates of serologic non-response | Standard follow-up at 6-month intervals |
Practical Points for HIV-Syphilis Co-Infection
- All HIV-positive patients should be screened for syphilis at diagnosis and at least annually thereafter (more frequently if high-risk behavior)
- All syphilis patients should be tested for HIV — co-infection is common
- CSF pleocytosis interpretation: In HIV+ patients on ART with suppressed viral load, CSF WBC >20/μL suggests co-existing neurosyphilis; in untreated HIV, even mild pleocytosis may be due to HIV alone — CSF VDRL reactivity becomes the key discriminator
- ART and syphilis: Effective ART may reduce the risk of neurosyphilis; ART immune reconstitution can unmask previously subclinical neurosyphilis (immune reconstitution inflammatory syndrome — IRIS)
- Re-infection: Syphilis does not confer lasting immunity; re-infection is common, particularly in high-risk populations; rising RPR titers in a treated patient should prompt evaluation for re-infection vs. treatment failure
Special Scenarios
Gummatous Neurosyphilis
- Gumma: Granulomatous lesion occurring in the brain parenchyma or meninges in late (tertiary) syphilis
- Imaging: Solitary or multiple dural-based or parenchymal enhancing lesions; may mimic meningioma or sarcoidosis
- Treatment: Responds well to IV penicillin; surgical resection usually not needed
Congenital Neurosyphilis
- Transmission: Transplacental, primarily during secondary syphilis
- Early manifestations (<2 years): Rhinitis (snuffles), hepatosplenomegaly, rash, osteochondritis; meningitis may cause hydrocephalus
- Late manifestations (>2 years): Hutchinson triad (interstitial keratitis, Hutchinson teeth, CN VIII deafness), saddle nose deformity, saber shins
- Treatment: IV penicillin G for 10 days in neonates
Syphilis as the "Great Imitator"
Syphilis can mimic virtually any neurologic condition. Consider syphilis testing in the evaluation of:
- Unexplained aseptic meningitis
- Stroke in young patients
- Progressive dementia (especially with psychiatric features)
- Unexplained myelopathy or radiculopathy
- Unexplained cranial neuropathies
- Unexplained uveitis, optic neuritis, or hearing loss
- Sensory ataxia with areflexia
- Any combination of the above with suggestive social history
References
- Ropper AH. Neurosyphilis. N Engl J Med. 2019;381(14):1358-1363.
- Workowski KA, Bachmann LH, Chan PA, et al. Sexually transmitted infections treatment guidelines, 2021. MMWR Recomm Rep. 2021;70(4):1-187.
- Marra CM. Neurosyphilis. Continuum (Minneap Minn). 2015;21(6 Neuroinfectious Disease):1714-1728.
- Ghanem KG, Ram S, Rice PA. The modern epidemic of syphilis. N Engl J Med. 2020;382(9):845-854.
- Hobbs E, Vera JH, Marks M, Barber AC, Schaffalitzky de Muckadell OB,";"; Neurosyphilis in patients with HIV. Pract Neurol. 2018;18(3):211-218.
- Marra CM, Maxwell CL, Tantalo L, et al. Normalization of cerebrospinal fluid abnormalities after neurosyphilis therapy: does HIV status matter? Clin Infect Dis. 2004;38(7):1001-1006.
- Marra CM, Maxwell CL, Smith SL, et al. Cerebrospinal fluid abnormalities in patients with syphilis: association with clinical and laboratory features. J Infect Dis. 2004;189(3):369-376.
- Tuddenham SA, Zenilman JM. Syphilis. In: Bennett JE, Dolin R, Blaser MJ, eds. Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases. 9th ed. Elsevier; 2020:2865-2892.
- Gonzalez H, Koralnik IJ, Marra CM. Neurosyphilis. Semin Neurol. 2019;39(4):448-455.
- Marra CM. Update on neurosyphilis. Curr Infect Dis Rep. 2009;11(2):127-134.
- Centers for Disease Control and Prevention. Sexually transmitted disease surveillance 2022. US Department of Health and Human Services; 2024.
- Marra CM, Tantalo LC, Maxwell CL, et al. The rapid plasma reagin test cannot replace the Venereal Disease Research Laboratory test for neurosyphilis diagnosis. Sex Transm Dis. 2012;39(6):453-457.
- Drago F, Merlo G, Ciccarese G, et al. Changes in neurosyphilis presentation: a survey on 286 patients. J Eur Acad Dermatol Venereol. 2016;30(11):1886-1900.
- Janier M, Unemo M, Dupin N, Tiplica GS, Potocnik M, Patel R. 2020 European guideline on the management of syphilis. J Eur Acad Dermatol Venereol. 2021;35(3):574-588.